Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it has received a complete response letter from the US Food and Drug Administration regarding New Drug Applications (NDAs) for alogliptin and fixed-dose combination (FDC) alogliptin and pioglitazone (Actos). Takeda has previously received a CRL for the product and refilled its submission last year (The Pharma Letter July 27, 2011).
Takeda says it recently provided post-marketing data from outside the USA, and has been in discussion with the FDA. The FDA has requested additional data which Takeda believes it can supply to the agency from post-marketing data from outside the USA, as well as data from its ongoing clinical trial program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze